Shanghai Fosun Pharmaceutical Group (SHA:600196) subsidiary Henlius (HKG:2696) signed a cooperation and license agreement with Palleon.
The two parties will cooperate on developing Palleon's E-602 product and related combination therapy solutions in the field and commercialization in their respective licensed regions, according to a Thursday filing with the Shanghai bourse.
Henlin shall pay Palleon royalties ranging between 8% and 12%, based on the annual net sales of the licensed products in the Henlin licensed territory.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments